Qiagen (QGEN) investor relations material

Executive summary

• Achieved 24th consecutive quarter meeting or exceeding targets, with Q3 2025 net sales reaching $533 million, up 6% year-over-year, and adjusted EPS of $0.61, both exceeding guidance.

• Portfolio expansion included the acquisition of Parse Biosciences for $225 million, strengthening the position in the high-growth single-cell market, and a $500 million synthetic share repurchase to be completed in January 2026.

• CEO Thierry Bernard will step down after a successor is appointed, marking a leadership transition.

• Shareholder returns enhanced by a $500 million share repurchase program and a $54 million dividend in 2025.

• Operating income margin improved, reflecting efficiency gains and lower operating expenses.

Financial highlights

• Net sales rose 6% to $533M; core sales up 6% CER year-over-year, with adjusted diluted EPS at $0.61, above outlook.

• Adjusted operating income margin steady at 29.6% of sales, absorbing currency and tariff headwinds.

• Operating cash flow for nine months was $466M, including $45M in restructuring payments; free cash flow was $336M, slightly below prior year due to higher IT investments.

• Net income for Q3 2025 was $130M, up 33% year-over-year; adjusted net income was $133M.

• Cash, cash equivalents, and short-term investments totaled $1.7B as of September 30, 2025.

Outlook and guidance

• Raised adjusted EPS target for 2025 to $2.38 CER, up $0.10 from initial guidance.

• Reaffirmed net sales growth of 4%-5% CER for 2025; core portfolio expected to grow 5%-6% CER.

• Q4 2025 net sales expected to be steady CER vs. Q4 2024; adjusted EPS for Q4 expected at $0.60 CER.

• Parse acquisition expected to add about $40M in sales in 2026, initially dilutive to EPS by $0.04 in 2026, accretive from 2028.

• Additional restructuring costs of ~$10M expected in Q4 2025.